AAPL   317.86 (+0.36%)
MSFT   179.09 (-1.37%)
AMZN   2,395.66 (-1.08%)
NVDA   338.55 (-2.91%)
CGC   20.32 (+1.55%)
BABA   200.85 (-0.44%)
MU   45.85 (+0.11%)
TSLA   817.77 (-0.13%)
AMD   52.31 (-1.65%)
T   31.60 (+2.50%)
ACB   15.74 (+0.83%)
F   6.06 (+3.77%)
DIS   123.53 (+2.13%)
BAC   25.62 (+5.48%)
AAPL   317.86 (+0.36%)
MSFT   179.09 (-1.37%)
AMZN   2,395.66 (-1.08%)
NVDA   338.55 (-2.91%)
CGC   20.32 (+1.55%)
BABA   200.85 (-0.44%)
MU   45.85 (+0.11%)
TSLA   817.77 (-0.13%)
AMD   52.31 (-1.65%)
T   31.60 (+2.50%)
ACB   15.74 (+0.83%)
F   6.06 (+3.77%)
DIS   123.53 (+2.13%)
BAC   25.62 (+5.48%)
AAPL   317.86 (+0.36%)
MSFT   179.09 (-1.37%)
AMZN   2,395.66 (-1.08%)
NVDA   338.55 (-2.91%)
CGC   20.32 (+1.55%)
BABA   200.85 (-0.44%)
MU   45.85 (+0.11%)
TSLA   817.77 (-0.13%)
AMD   52.31 (-1.65%)
T   31.60 (+2.50%)
ACB   15.74 (+0.83%)
F   6.06 (+3.77%)
DIS   123.53 (+2.13%)
BAC   25.62 (+5.48%)
AAPL   317.86 (+0.36%)
MSFT   179.09 (-1.37%)
AMZN   2,395.66 (-1.08%)
NVDA   338.55 (-2.91%)
CGC   20.32 (+1.55%)
BABA   200.85 (-0.44%)
MU   45.85 (+0.11%)
TSLA   817.77 (-0.13%)
AMD   52.31 (-1.65%)
T   31.60 (+2.50%)
ACB   15.74 (+0.83%)
F   6.06 (+3.77%)
DIS   123.53 (+2.13%)
BAC   25.62 (+5.48%)
Log in

NYSEAMERICAN:PFNXPfenex Stock Price, Forecast & News

$6.87
-0.01 (-0.15 %)
(As of 05/27/2020 09:46 AM ET)
Add
Compare
Today's Range
$6.87
Now: $6.87
$7.06
50-Day Range N/A
52-Week Range
$5.26
Now: $6.87
$14.00
Volume8,231 shs
Average Volume344,221 shs
Market Capitalization$235.09 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.
Read More
Pfenex logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PFNX
Previous SymbolNYSEMKT:PFNX
CUSIPN/A
CIKN/A
Phone+1-858-3524400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees71
Market Cap$235.09 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.

Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Pfenex?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pfenex.

When is Pfenex's next earnings date?

Pfenex is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Pfenex.

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) issued its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.07. The biotechnology company had revenue of $0.68 million for the quarter, compared to analysts' expectations of $3.75 million. View Pfenex's earnings history.

What price target have analysts set for PFNX?

5 brokerages have issued twelve-month price objectives for Pfenex's stock. Their forecasts range from $9.00 to $20.00. On average, they expect Pfenex's share price to reach $15.25 in the next year. This suggests a possible upside of 122.0% from the stock's current price. View analysts' price targets for Pfenex.

Has Pfenex been receiving favorable news coverage?

Media headlines about PFNX stock have been trending negative this week, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pfenex earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutPfenex.

Who are some of Pfenex's key competitors?

What other stocks do shareholders of Pfenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfenex investors own include Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), Immunomedics (IMMU), Ocular Therapeutix (OCUL), Opko Health (OPK), Ring Energy (REI), Ring Energy (REI), TG Therapeutics (TGTX), Verastem (VSTM) and Bausch Health Companies (BHC).

Who are Pfenex's key executives?

Pfenex's management team includes the following people:
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 47)
  • Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 61)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 51)
  • Dr. Hubert C. Chen, Advisor (Age 50)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 55)

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

Who are Pfenex's major shareholders?

Pfenex's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (9.73%), Primecap Management Co. CA (9.54%), Blair William & Co. IL (7.92%), BlackRock Inc. (6.03%), Orbimed Advisors LLC (3.81%) and Telemark Asset Management LLC (2.05%). Company insiders that own Pfenex stock include Evert B Schimmelpennink, Patrick K Lucy, Phillip M Schneider and Robin Campbell. View institutional ownership trends for Pfenex.

Which institutional investors are selling Pfenex stock?

PFNX stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Nuveen Asset Management LLC, Squarepoint Ops LLC, Invesco Ltd., Primecap Management Co. CA, EAM Investors LLC, Two Sigma Investments LP, and EAM Global Investors LLC. View insider buying and selling activity for Pfenex.

Which institutional investors are buying Pfenex stock?

PFNX stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Telemark Asset Management LLC, Tarsadia Capital LLC, AQR Capital Management LLC, RK Capital Management LLC, Park West Asset Management LLC, Calamos Advisors LLC, and Russell Investments Group Ltd.. Company insiders that have bought Pfenex stock in the last two years include Evert B Schimmelpennink, Phillip M Schneider, and Robin Campbell. View insider buying and selling activity for Pfenex.

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $6.87.

How big of a company is Pfenex?

Pfenex has a market capitalization of $235.09 million. Pfenex employs 71 workers across the globe.

What is Pfenex's official website?

The official website for Pfenex is www.pfenex.com.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.